VC Deals (14 deals, $480M)
HealthiPASS, a Chicago-based patient check-in and payments company, has raised an undisclosed amount of Series A funding. OCA Ventures led the round, and was joined by Beverly Capital and MPG Equity Partners
Humacyte, a Morrisville, N.C.-based developer of human tissue-based products for application in regenerative medicine and vascular surgery, has raised $150 million in Series B funding. Backers include Access Industries, Bangkok Bank Public Company Ltd., Brady Dougan, Pacific Eagle Asset Management, Reignwood Group and Gavril Yushvaev. The company said that a second Series B tranche is expected to occur following the achievement of a clinical milestone
Gritstone Oncology, a San Francisco-based developer of personalized cancer therapeutics, has raised $102 million in Series A funding. Versant Venturesand The Column Group co-led the round, and were joined by Clarus Ventures, Frazier Healthcare Partners, Redmile Group, Casdin Capital\ and Transformational Healthcare Opportunity
Attune Technologies,, an Indian developer of cloud software for hospitals and medical labs, has raised $10 million in Series B funding. Qualcomm Venturesled the round, and was joined by Norwest Venture Partners
Vittamed Corp., a Boston-based developer of a non-invasive intracranial pressure monitor, has raised $10 million in Series A funding. Xeraya Capitalled the round via a special purpose vehicle, and was joined by return backer Imprimatur Capital
Collective Health, a San Mateo, Calif.-based provider of enterprise health insurance software and services, has raised $81 million in Series C funding.Google Ventures led the round, and was joined by NEA, Founders Fund, Maverick Capital, Redpoint Ventures and RRE Ventures
Silk Road Medical, a Sunnyvale, Calif.-based developer of surgical solutions for treating strokes, has raised $57 million in new equity and debt financing. CRGled the debt financing, and also participated on the equity alongside Warburg Pincus and The Vertical Group
Portal Instruments, a Cambridge, Mass.-based drug delivery statrtup focused on injectable biologics for chronic diseases, has raised $25 million in Series B funding ($15m of which is a milestone-based tranche). 5AM Ventures led the round, and was joined by return backer Sanofi Sunrise
Amino, a San Francisco-based personalized doctor search engine for consumers, has raised $19.4 million in pre-launch funding from Accel Partners, CRV and Rock Health
Science 37, a Los Angeles-based provider of “end-to-end clinical trial services without geographic limitations,” has raised $6.5 million in Series A funding co-led by Lux Capital and dRx Capital
Cohera Medical, a Pittsburgh-based developer of absorbable surgical adhesives and sealants, has raised $50 million in growth equity funding from KKR. The company previously raised more than $25 million from firms like Kern Whelan Capital
Sequana Medical AG, a Swiss developer of an implantable pump systems that manage excess fluid within the body, has raised CHF 9 million ($9.3m) in new Series C funding. Salus Partners and Quest for Growth were joined by return backers NeoMed Management, VI Partners, Biomed Invest, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners
IntelliCyt Corp., an Albuquerque, N.M.-based provider of platforms to accelerate drug discovery, has raised $5.4 million in new equity funding. Arboretum Ventures led the round, and was joined by fellow return backers Prolog Ventures, Verge Fund, and New Mexico Community Capital. The company also secured a $2 million debt facility from Oxford Finance
PE Deals (3 deals)
Vision Radiology, a Pittsburgh-based provider of remote radiology services to emergency rooms, has secured an undisclosed amount of private equity funding from Acacia Partners
Epic Health Services Inc., a Dallas-based provider of pediatric skilled nursing and therapy, has acquired Medco, a Houston, Texas-based provider of enteral therapy services, respiratory equipment and incontinence products. No financial terms were disclosed. EHS is a portfolio company of Webster Capital
Berkshire Partners has acquired a majority stake in Affordable Care Inc., a Raleigh, N.C.-based support organization for affiliated dental practices that focus exclusively on tooth replacement services, from American Capital Equity. No financial terms were disclosed
IPO Deals (7 deals)
Basilea Pharmaceutica Ltd., a Swiss developer of drugs for resistant fungal infections, has filed for a $189.52 million IPO. It plans to trade on the Nasdaq under ticker symbol BSLN, which is the same symbol that its stock currently trades on via the SIX Swiss Exchange. Cowen & Co. and Guggenheim Securities are serving as lead underwriters. Shareholders include Franklin Resources (8.74% pre-IPO stake) and HBM Healthcare Investors (7.82%)
BeiGene Ltd., a Beijing-based developer of immune-oncology therapeutics, has filed for a $100 million IPO. It plans to trade on the Nasdaq under ticker symbol BGNE, with Goldman Sachs, Morgan Stanley and Cowen & Co. serving as lead underwriters. The company reports a $15.8 million net loss on $2.8 million in revenue for the first six months of 2015. It has raised over $170 million in VC funding from Baker Brothers Life Sciences (25.8% pre-IPO stake), Hillhouse Capital (9.9%), Merck Sharp & Dohme Research (7.7%) and CTIC Capital Partners (6.4%)
Ellipse Technologies Inc., an Aliso Viejo, Calif.-based developer of devices for orthopedic implant systems, has filed for a $75 million IPO. It plans to trade on the Nasdaq under ticker symbol MGEC, with Piper Jaffray and William Blair serving as lead underwriters. Shareholders include HBM Healthcare Investors (29.9% pre-IPO stake), Wexford Capital (18%) and HBM-MedFocus (12.9%)
Merus BV, a Dutch immuno-oncology company focused on bispecific antibody therapeutics, has filed for a $60 million IPO. It plans to trade on the Nasdaq under ticker symbol MRUS, with Citigroup and Jefferies serving as lead underwriters. The company has raised over $170 million in VC funding from firms like Novartis Bioventures (13.7% pre-IPO stake), Bay City Capital (13.7%), Aglaia Oncology Fund (11%), Johnson & Johnson (10.6%), Pfizer Inc. (9.1%), Sofinnova Venture Partners (8.2%), Novo AS (7.8%), Baker Brothers Life Sciences (7.2%) and Coöperatief LSP (6.8%)
MyoKardia Inc., a South San Francisco-based provider of therapies for genetic heart disease, set its IPO terms to around 4.69 million shares at between $15 and $17 per share. It would have an initial market cap of approximately $408 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol MYOK, with Credit Suisse and Cowen & Co. serving as lead underwriters. MyoKardia reports a $12.2 million net loss on $7.1 million in collaboration and license revenue for the first half of 2015. It has raised over $90 million in VC funding, from firms like Third Rock Ventures (52.67% pre-IPO stake), Fidelity (13.19%), Aventis Inc. (11.22%), Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences and BioBridge
Kura Oncology, a La Jolla, Calif.-based developer of treatments for solid tumors and blood cancers, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol KURA, with Citigroup and Leerink Partners serving as lead underwriters. The pre-revenue company has raised in VC funding, from firms like Fidelity (12.73% pre-IPO stake), EcoR1 Capital (9.99%), Arch Venture Partners (9.27%), Tavistock Life Sciences, Partner Fund Management and Nextech Invest
Viventia Bio Inc., a Canadian developer of targeted protein therapeutics for cancer, has filed for an $86.25 million IPO. The pre-revenue company plans to trade on the Nasdaq under ticker symbol VITA, with Leerink Partners, Cowen & Co. and Guggenheim Securities serving as lead underwriters
Other Deals (2 deals)
Valeant Pharmaceuticals (TSX: VRX) said that it will explore selling or spinning off its neurological drug unit, which has been criticized for price increases
PatientSafe Solutions, a San Diego-based provider of connected workflow and care coordination solutions for healthcare, has acquired the assets of Vree Health, an Annandale, N.J.-based patient engagement and care management platform, from Merck. No financial terms were disclosed. PatientSafe shareholders include EDBI, Merck Global Health Innovation Fund, Camden Partners, TPG Biotech and Psilos Group
Navient (Nasdaq: NAVI) has acquired Xtend Healthcare, a Hendersonville, Tenn.-based provider of revenue cycle software for the healthcare market. No financial terms were disclosed, except that Xtend is expected to generate around $70 million in 2015 revenue. Sellers are WestView Capital Partnersand Brentwood Capital Partners
Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg
#healthtech #asia
